Nasdaq GlobeNewswire

Cisco Brings Visibility and Insights to IT's Biggest Blind Spot: The WAN

Del
  • Cisco delivers intent-based networking for the wide area network (WAN) with new analytics and assurance solutions.
  • Cisco solutions provide the visibility and insight that allow customers to quickly isolate and resolve issues in the WAN.
  • Cisco solutions provide deep learning capabilities that can predict issues before they happen, potentially saving organizations from experiencing costly downtime.

MELBOURNE, Australia, March 07, 2018 (GLOBE NEWSWIRE) -- Cisco today announced new innovations built to bring visibility to IT's biggest blind spot: the wide-area network (WAN). Made up of disparate networks outside of the control of IT, the WAN connects employees to applications, no matter where those employees might be. The fragmented nature of the WAN means that IT often has limited ability to specifically determine problems and get real-time information. Now, Cisco is helping IT by providing the capability to forecast WAN problems before they happen, while quickly isolating and fixing issues when they do occur.

Over the past few years, the rise of multicloud IT environments has exacerbated the traditional complexity of the WAN and magnified its challenges. A recent IDC study (Worldwide SD-WAN Survey Special Report September 2017) discovered that almost 3 out of 10 organizations considered network outages to be a top WAN concern, with the same number stating they need better visibility and analytics to manage application and WAN performance.

Building on the company's recent push toward intent-based networking, Cisco is driving this network revolution to the WAN. Today, Cisco is introducing innovations to provide IT with the vital visibility and insight into the WAN that will help keep businesses up and running:

  • Cisco® SD-WAN vAnalytics provide IT with visibility, forecasting for applications and bandwidth planning, "what-if" scenarios, and actionable recommendations.
  • Cisco Meraki(TM) Insight helps IT administrators optimize the end user experience by providing valuable understanding into WAN and SaaS application performance, significantly reducing the time it takes to isolate and resolve issues.

"We have set an ambitious goal for ourselves of transforming the entire network, from campus to branch, data center to edge," said Scott Harrell, senior vice president and general manager, Enterprise Networking at Cisco. "The WAN is a vital part of the network and is one of the toughest to manage. As we bring insight into the WAN with these new innovations, we get closer to delivering end-to-end intent-based networking to help our customers eliminate downtime and save money."

Cisco provides a full portfolio of services to help accelerate a customer's journey to intent-based networking for the WAN. Services experts help customers create a customized roadmap for success, speed deployment, and maximize network performance.

Cisco SD-WAN vAnalytics 
Today, Cisco is introducing Cisco SD-WAN vAnalytics (based on Viptela® technology). Built as a cloud-based SaaS solution, the technology provides comprehensive data, analysis, and corrective actions across the WAN, including branch offices, multicloud endpoints, and multiple service providers. Using vAnalytics, customers can forecast how potential policy changes to the WAN could affect application performance. It can also provide intelligent recommendations about how to deliver optimal application experiences. For example, with vAnalytics, organizations can now better understand how a rollout of IP-enabled security cameras or a cloud-based application across multiple branch offices could affect WAN infrastructure. vAnalytics can help enterprises identify the stress points and necessary policy changes, helping customers avoid technology growing pains.

"With over 600 branch offices and more than 5,000 employees, we rely on cloud applications and an always connected workplace to serve our customers," said Peter Castle, senior network engineer, Reece Ltd. "Our business requires a secure, scalable, and high-performance WAN. With vManage, we can centrally deploy branch applications and services rapidly, and we have been able to dramatically improve branch availability and bandwidth utilization with the rich analytics this platform provides. We are looking forward to the additional functionality we will be able to achieve with the even richer application visibility that vAnalytics will provide us."

Cisco Meraki Insight
Today, Cisco Meraki is also announcing Meraki Insight, a new tool integrated into the Meraki dashboard to help IT maintain a better end-user experience. The solution provides end-to-end visibility with application and WAN performance analytics. With Meraki Insight, customers can understand and troubleshoot both internal and external issues that can contribute to poor user experience for applications hosted in a remote data center or in the cloud. Meraki Insight helps IT achieve faster time to resolution for performance issues by more accurately pinpointing the source of the problem.

"At Extra Space Storage, as we move more and more of our business-critical applications to the cloud, it is imperative to maintain a high-performance network," said Jacob Stimpson, senior analyst, IT Business at Extra Space Storage. "Meraki Insight gives us the network and SaaS application visibility we need to quickly remediate issues and ensure a great end-user experience."

Availability

  • Cisco SD-WAN vAnalytics is available now via a Cisco SD-WAN license tier.
  • Cisco Meraki Insight is expected to be available in Cisco's Q3. It will be available as a separate license.

Additional Resources

About Cisco
Cisco (NASDAQ:CSCO) is the worldwide technology leader that has been making the Internet work since 1984. Our people, products, and partners help society securely connect and seize tomorrow's digital opportunity today. Discover more at newsroom.cisco.com and follow us on Twitter at @Cisco.

Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the United States and certain other countries. A listing of Cisco's trademarks can be found at  www.cisco.com/go/trademarks .  All other trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company. Many of the products and features described herein remain in varying stages of development and will be offered on a when-and-if-available basis. This roadmap is subject to change at the sole discretion of Cisco, and Cisco will have no liability for delay in the delivery or failure to deliver any of the products or features set forth in this document. This document is Cisco Public Information.

Contact:

Taylor Hassman
Phone Number: 415-610-6075
Email: thassman@cisco.com

 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cisco via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

World Conference on Lung Cancer Tuesday Press Conference: Improving the Cure Rate for Stage III Lung Cancer25.9.2018 19:26Pressemelding

TORONTO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Today’s press conference at the International Association for the Study of Lung Cancer’s (IASLC’s) 19th World Conference on Lung Cancer (WCLC) featured some of the year’s most innovative research in both small cell and non-small cell lung cancer. Frances Shepherd, M.D., FRCPC, WCLC honorary chair, medical oncologist at Princess Margaret Cancer Centre and former president of the IASLC (2005-2007), opened with the practice-changing importance of data shared this morning at the 2018 Presidential Symposium. Dr. Shepherd continued with background on the current inoperability and low cure rate of Stage III lung cancers, which comprise 1/3 of all lung cancers. Ground breaking data presented during today’s symposium demonstrated an advancement in disease treatment not seen for many years. PACIFIC study shows durvalumab improves overall survival in patients with unresectable non-small cell lung cancer without progression after chemoradiotherapy Recent

Manufacturing Leadership Forum Will Highlight Enabling Industry 4.0 with Analytics25.9.2018 15:06Pressemelding

Upcoming Dates in Houston, Texas and Antwerp, Belgium PORTLAND, Ore., Sept. 25, 2018 (GLOBE NEWSWIRE) -- New dates for The Manufacturing Leadership Forum were announced today including Houston, Texas, US on October 9, 2018 at the Petroleum Club of Houston and on November 28, 2018 in Antwerp, Belgium at the Lindner WTC Hotel & City Lounge. The events are sponsored by Northwest Analytics, a leading provider of manufacturing intelligence and SPC software solutions for manufacturers. This premier manufacturing analytics educational event focuses on enabling Industry 4.0 programs with manufacturing analytics. The Forums will feature keynotes and case-study presentations from globally-recognized leaders in the application of manufacturing analytics. In its fourth year, The Manufacturing Leadership Forum will open with a keynote from analytics visionary, Dr. Lloyd Colegrove, Director of Data Services & Fundamental Problem Solving at The Dow Chemical Company. “The Manufacturing Leadership Foru

SpeeDx Begins Multisite U.S. Clinical Trials of ResistancePlus® MG Test25.9.2018 14:00Pressemelding

Test supports international guidelines for treating antibiotic resistant STI SYDNEY, Australia, Sept. 25, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. today announced the start of patient testing in their multisite U.S.-based clinical trials for ResistancePlus® MG (not available for sale in the U.S.). The molecular diagnostic test detects the sexually transmitted infection (STI) Mycoplasma genitalium, also known as Mgen or MG, along with genetic markers linked to antibiotic resistance. In recent years, Mgen prevalence has increased globally and developed high rates of resistance to the common antibiotic treatment, azithromycin. "This test is an exciting new development that will increase the precision of patient care for patients impacted by Mycoplasma genitalium - a common sexually transmitted infection with limited treatment options,” notes Dr Maria Trent, Professor of Pediatrics and Public Health at Johns Hopkins Medicine. The SpeeDx ResistancePlus MG test is in use in laboratories acr

Checkpoint Therapeutics Announces Presentation of Updated Data from Phase 1/2 Trial of EGFR Inhibitor CK-10125.9.2018 14:00Pressemelding

Data were featured in an oral presentation at the IASLC 19th World Conference on Lung Cancer Phase 3 trial in treatment-naïve EGFR mutation-positive NSCLC patients targeted to commence in 2019 NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that positive preliminary safety and efficacy data from an ongoing Phase 1/2 clinical trial of CK-101 were presented yesterday in an oral presentation at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer in Toronto. The oral presentation included further details on, and updates from, the dataset announced previously. CK-101 is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) being evaluated in advanced non

Novavax Initiates Phase 2 Clinical Trial of NanoFlu™ in Older Adults25.9.2018 13:00Pressemelding

First participants enrolled in Phase 2 clinical trial of quadrivalent NanoFlu formulations Top-line immunogenicity and safety data expected in the first quarter of 2019 Phase 2 results will support meeting with the U.S. Food and Drug Administration (FDA) and Phase 3 clinical trial design GAITHERSBURG, Md., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced the initiation of a Phase 2 dose and formulation confirmation clinical trial in older adults of NanoFlu, its nanoparticle seasonal influenza vaccine candidate. “Initiating this Phase 2 clinical trial of NanoFlu is an important milestone for Novavax,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “With top-line results expected in the first quarter of 2019, we plan to discuss these data with the FDA at an ‘End of Phase 2’ meeting and to agree on the appropriate Phase 3 clinical trial design to support licensure via accelerated approval. We continue to believe NanoFlu is a differen

CGAP Launches Photo and Video Contest Theme for 2018: Financial Inclusion in Africa25.9.2018 13:00Pressemelding

This year's CGAP contest is the first ever to accept short video entries WASHINGTON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- The Consultative Group to Assist the Poor’s (CGAP) 13th annual photo contest, launched today, is seeking striking images on financial inclusion in Africa. For the first time, short video submissions on Africa also will be accepted. Entries may be submitted through December 14, 2018. Each contestant may submit up to 20 photos or videos to compete for the Grand Prize worth US$ 2,000. This year CGAP is looking for original and compelling photographs and short videos that tell the story of how financial services empower poor people and communities in Africa. The region is a center for financial innovation -- home to M-Pesa, the mobile money service launched a decade ago now replicated across markets worldwide; host to vibrant FinTech and e-commerce companies; and to a growing off-grid sector that leverages digital finance. Together these innovators contribute toward lifti

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom